CHAPTER 7: mGlu2 Receptor Positive Allosteric Modulators Check Access

Positive allosteric modulation of the metabotropic glutamate type 2 (mGlu2) receptor has emerged as a promising mechanism for the treatment of central nervous system diseases, with the potential to provide a new and more effective avenue for the treatment of schizophrenia. Since the first discovery of mGlu2 receptor positive allosteric modulators (PAMs) multiple families of mGlu2 modulators have been reported. This chapter summarises the state of the art of the mGlu2 PAM arena by reviewing the different chemotypes reported to date, their proposed binding modes and the development status of those that have advanced into clinical evaluation.